CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Mirabegrondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02916693
NCT02916693Phase 2Completed
CompareCT.gov

Mirabegron For Erectile Dysfunction

Johns Hopkins University·interventional·Posted Sep 27, 2016·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating Mirabegron for Erectile Dysfunction and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The only class of oral erectile dysfunction (ED) medication on the market are the phosphodiesterase Type 5 inhibitors (PDE5i). This pilot study is being done to evaluate the effect of Mirabegron, an oral beta-3 adrenergic agonist, on men with both Overactive Bladder (OAB) symptoms and mild to moderate ED.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction, Overactive Bladder, Urinary Incontinence
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 27, 2016
Enrollment StartAug 1, 2017
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.8 years ago

Interventions

Mirabegrondrug

FDA-approved, beta 3 agonist for over active bladder